Trial reportClinical and experimental dental research2026
Clinical Evaluation of Three Direct Pulp Capping Materials in Caries-Induced Pulpitis of Mature Permanent Teeth: A Randomized Controlled Trial.
Trial report in Clinical and experimental dental research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
objectivesDirect pulp capping (DPC) preserves pulp vitality in caries-exposed permanent teeth, but clinical evidence comparing different capping materials and identifying prognostic factors remains limited. This study evaluated the success of DPC with iRoot BP Plus, mineral trioxide aggregate (MTA), and calcium hydroxide (CH), and explored factors associated with treatment outcomes. MATERIAL AND
methodsIn this single-blind, parallel-group, superiority randomized trial, 120 patients with caries-induced reversible pulpitis were equally assigned to CH, MTA, or iRoot BP Plus. The primary outcome was 12-month success, defined by combined clinical and radiographic criteria. Associations between baseline clinical factors and 12-month success were evaluated. Secondary analyses included success at 3 and 6 months.
resultsAt 12 months, 81 of 120 randomized patients (67.5%) were available for evaluation. The overall success rate was 88.9%. Success rates were 88.5% for iRoot BP Plus (n = 26), 93.1% for MTA (n = 29), and 84.6% for CH (n = 26), with no significant differences between groups (p = 0.6). Failures were significantly associated with lesions confined to the proximal surface (p = 0.001) at 12 months, while exposure size > 1 mm (p = 0.024) and anterior teeth (p = 0.018) were additional risk factors at 6 months. Kaplan-Meier analysis showed high survival across all groups (log-rank p = 0.66) and confirmed the influence of these risk factors. No adverse events were reported.
conclusionsDPC achieved high short-term success in mature permanent teeth in MTA, CH, and iRoot BP Plus. Prognostic factors such as caries location, tooth position, and exposure size remain critical for case selection.
trial registrationnumber: ChiCTR2100047588; Chinese Clinical Trial Register.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.